Is WELL Health a Good Stock to Buy Now?

Let’s assess the buying opportunity in WELL Health by looking at its second-quarter performance and growth prospects.

| More on:

WELL Health Technologies (TSX:WELL) reported a solid second-quarter performance last week, with its patient visits and revenue growing in double digits. After reporting its second-quarter performance, the company’s management has raised its 2024 guidance. Despite its impressive performance and raising of guidance, the company’s stock price has remained flat and is down 9.5% compared to its 52-week high. Let’s assess whether WELL Health would be a buy at these levels by looking at its second-quarter performance and growth prospects.

WELL Health’s second-quarter performance

In the June-ending quarter, WELL Health reported revenue of $243.1 million, representing a 42% year-over-year growth. An organic growth of 21% and acquisitions over the last four quarters drove its revenue growth. It had around 1.4 million patient visits and 2.1 million patient interactions during the quarter, representing a year-over-year growth of 38% and 48%, respectively.

Its gross profits increased by 18% to $107.4 million. Meanwhile, its gross profit margin contracted from 53.1% to 44.2% amid the acquisition of lower gross margin businesses over the last four quarters. The company generated an adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) of $30.9 million, representing an 11% increase from $27.8 million in the previous year’s quarter. However, the adjusted EBITDA to WELL shareholders stood at $23 million, representing a 3% year-over-year increase.

Further, WELL Health’s net income came in at $117 million, a substantial increase from $19.6 million in the previous year’s quarter. The increase was primarily due to unrealized gains of its investment in HEALWELL AI. However, removing special or one-time items, its adjusted net income stood at $12.3 million, representing a year-over-year decline of 14.6%. The free cash flows attributed to the company’s shareholders stood at $8.7 million, 7.4% lower than its prior year’s quarter. Now, let’s look at WELL Health’s growth prospects.

WELL Health’s growth prospects

The growing popularity of virtual services, digitization of patient records, and increased usage of software solutions in the healthcare sector have expanded WELL Health’s addressable market. Meanwhile, the company focuses on capital-efficient growth opportunities with effective cost management that could lead to robust growth and sustained cash flow.

It has partnered with Microsoft to enhance digital healthcare across North America. The partnership would help WELL Health scale its business, optimize costs, improve operational efficiency, and ensure data security. The company continues to invest in artificial intelligence (AI) to develop innovative tools and enhance AI and interoperability in the country’s healthcare sector. Further, in June, the company acquired 10 primary care clinics operated by Shoppers Drug Mart in British Columbia and Ontario. 

Amid its healthy second-quarter performance and high growth prospects, WELL Health has raised its 2024 guidance. The management now expects its 2024 topline to come within $970-$990 million, with the midpoint representing a 26.3% increase from the previous year’s quarter. Meanwhile, the midpoint of its adjusted EBITDA guidance represents a 12.4% year-over-year growth. Considering all these factors, I believe WELL Health’s growth prospects look healthy.

Investors’ takeaway

Supported by its solid quarterly performances, WELL Health has been one of the top performers this year, delivering over 18.5% returns. Despite the stock price increase, the company’s valuation looks attractive, with its NTM (next 12 months) price-to-sales and price-to-book multiples at 1.1 and 1.2, respectively. Considering its solid operating performances, growth prospects, and attractive valuation, I believe WELL Health would be an excellent buy at these levels.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. The Motley Fool recommends Microsoft. The Motley Fool has a disclosure policy.

More on Investing

Canada national flag waving in wind on clear day
Tech Stocks

Trump Trade: Canadian Stocks to Watch

With Trump returning to the presidency, there are some sectors that could boom in Canada, and others to watch. But…

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Investing

Is Canadian National Railway Worth Buying for its 2.2% Dividend Yield?

Let's dive into whether Canadian National Railway (TSX:CNR) is a top buy for long-term investors at this point in the…

Read more »

nuclear power plant
Energy Stocks

Is Cameco Stock Still a Buy?

Cameco stock recently reported earnings that showed the Westinghouse investment is creating some major costs. But that could change.

Read more »

cloud computing
Dividend Stocks

Insurance Showdown: Better Buy, Great-West Life or Manulife Stock?

GWO stock and MFC stock are two of the top names in insurance, but which holds the better outlook?

Read more »

analyze data
Dividend Stocks

Here’s Why the Average TFSA for Canadians Aged 41 Isn’t Enough

The average TFSA simply isn't enough for most Canadians in their early 40s. Here's how to catch up.

Read more »

A plant grows from coins.
Dividend Stocks

The Smartest Dividend-Growth Stocks to Buy With $1,000 Right Now

New dividend-growth investors should consider CN Rail (TSX:CNR) stock and another top play if they're looking to build wealth over…

Read more »

concept of real estate evaluation
Dividend Stocks

How to Earn a TFSA Paycheque Every Month and Pay No Taxes on It

Canadian REITs can turn your TFSA into a monthly paycheque machine for life. Here's how Morguard North American Residential REIT…

Read more »

Start line on the highway
Investing

2 No-Brainer Growth Stocks to Buy Now With $5,000 and Hold Long Term

Market conditions today are ideal for growth investing, and two rising stocks are no-brainer buys in November.

Read more »